Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 18, Issue 32, 2014, Pages 1-165

  Westwood, Marie ^a   Joore, Manuela ^b   Whiting, Penny ^a   van Asselt, Thea ^b   Ramaekers, Bram ^b   Armstrong, Nigel ^a   Misso, Kate ^a   Severens, Johan ^c   Kleijnen, Jos ^d  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DRUG COST; DRUG EFFECT; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PYROSEQUENCING; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; ECONOMICS; GENETICS; LUNG NEOPLASMS; METASTASIS; MORTALITY; MUTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84901346578     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18320     Document Type: Article

References (221)

1. National Institute for Health and Clinical Excellence (NICE). Gefitinib for the First-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. NICE technology appraisal guidance 192. London: NICE; 2010. http://guidance.nice.org.uk/TA192 (accessed 20 June 2012).
2. National Institute for Health and Clinical Excellence (NICE). Erlotinib for the First-Line Treatment of Locally Advanced or Metastatic EGFR-TK Mutation-Positive Non-Small Cell Lung Cancer. NICE technology appraisal guidance 258. London: NICE; 2012. www.nice.org.uk/nicemedia/live/13773/59789/59789.pdf (accessed 10 July 2012).
3. Office for National Statistics (ONS). Cancer Registrations in England, 2010: Number of New Cases Diagnosed by Site. London: ONS; 24 April 2012. www.ons.gov.uk/ons/rel/vsob1/cancer-registrations-in-england/2010/2010-cancer-registrations-in-england-statistical-bulletin-2.html#tab-Number-of-new-cases-diagnosed-by-site (accessed 20 June 2012).
4. Cancer Research UK. Lung Cancer: UK Incidence Statistics. London: Cancer Research UK, last updated 13 April 2012. http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/uk-lung-cancer-incidence-statistics (accessed 20 June 2012).
5. The NHS Information Centre. National Lung Cancer Audit Report 2011. Report for the Audit Period 2010. Leeds: The NHS Information Centre; 2011. www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NHS_IC_Lung_Cancer_AUDIT_2011_Interactive_PDF_V1.0.pdf (accessed 4 December 2012).
6. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65. http://dx.doi.org/10.1200/JCO.2005.08.043
7. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23. http://dx.doi.org/10.1158/0008-5472.CAN-04-2818
8. Huang S-F, Liu H-P, Li L-H, Ku Y-C, Fu Y-N, Tsai H-Y, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203. http://dx.doi.org/10.1158/1078-0432.CCR-04-1245
9. Romeri E, Baker A, Griffiths C. Mortality by deprivation and cause of death in England and Wales, 1999-2003. Health Stat Q 2006;32:19-34.
10. The NHS Information Centre. National Lung Cancer Audit Report. Key Findings about the Quality of Care for People with Lung Cancer in England Incorporating Headline and Completeness Data from Wales. Report for the Audit Period 2005. Leeds: The NHS Information Centre; 2006. www.ic.nhs.uk/webfiles/Services/NCASP/Cancer/Lung%20cancer%202006.pdf (accessed 20 June 2012).
11. Office for National Statistics (ONS). Cancer Registrations in England, 2010. Statistical Bulletin: ONS; 2012. www.ons.gov.uk/ons/dcp171778_263537.pdf (accessed 10 July 2012).
12. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-13. http://dx.doi.org/10.1097/JTO.0b013e3181f1c8de
13. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006;8:335-41. http://dx.doi.org/10.2353/jmoldx.2006.050104
14. Yung TKF, Chan KCA, Mok TSK, Tong J, To K-F, Lo YMD. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84. http://dx.doi.org/10.1158/1078-0432.CCR-08-2622
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. http://dx.doi.org/10.1056/NEJMoa040938
16. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. http://dx.doi.org/10.1016/S1470-2045(11)70184-X
17. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007;131:1628-34. http://dx.doi.org/10.1378/chest.06-1673
18. National Institute for Health and Clinical Excellence (NICE). Lung Cancer: the Diagnosis and Treatment of Lung Cancer (CG121). London: NICE; April 2011. http://guidance.nice.org.uk/CG121 (accessed 20 June 2012).
19. National Institute for Health and Clinical Excellence (NICE). Lung Cancer (Non-Small-Cell, First Line Treatment) - Pemetrexed (TA181). London: NICE; September 2009. www.nice.org.uk/TA181 (accessed 20 June 2012).
20. World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO; 1979. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf (accessed 4 December 2012).
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
22. Centre for Reviews and Dissemination (CRD). Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: University of York; 2009. www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed 23 March 2011).
23. National Institute for Health and Clinical Excellence (NICE). Diagnostics Assessment Programme Manual. Manchester: NICE, 2011. www.nice.org.uk/media/A0B/97/DAPManualFINAL.pdf (accessed 10 July 2012).
24. Cochrane Diagnostic Test Accuracy Working Group. Handbook for DTA Reviews: The Cochrane Collaboration, 2009. http://srdta.cochrane.org/handbook-dta-reviews (accessed 23 March 2011).
25. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011): The Cochrane Collaboration, 2011. www.cochrane-handbook.org/(accessed 23 March 2011).
26. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Inf Pract 2010;5:1-6.
27. Royle P, Waugh N. Should systematic reviews include searches for published errata? Health Info Libr J 2004;21:14-20. http://dx.doi.org/10.1111/j.1471-1842.2004.00459.x
28. Wright K, McDaid C. Is the retraction of journal articles in electronic journals and databases consistent and timely? A case study. Cochrane Colloquium, Cochrane Collaboration, Madrid, 19-22 October 2011.
29. Wright K, McDaid C. Reporting of article retractions in bibliographic databases and online journals. J Med Libr Assoc 2011;99:164-7. http://dx.doi.org/10.3163/1536-5050.99.2.010
30. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
31. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
32. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022
33. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-51. http://dx.doi.org/10.1093/biostatistics/kxl004
34. Harbord RM, Whiting P, Sterne JA, Egger M, Deeks JJ, Shang A, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008;61:1095-103. http://dx.doi.org/10.1016/j.jclinepi.2007.09.013
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58. http://dx.doi.org/10.1002/sim.1186
36. Benlloch S, Taron M, Botero ML, Bertran-Alamillo J, Mayo C, Gimenez Capitan A, et al. Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay. American Society of Clinical Oncology (ASCO) Annual Meeting, Collaborating to Conquer Cancer, 1-5 June 2012, Chicago, IL. Abstract 10596.
37. Sugio K, Uramoto H, Takenoyama M, Hanagiri T, Yasumoto K. Molecular targeted therapy and tailor-made therapy for lung cancer. Kyobu Geka 2008;61:37-42.
38. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Paper presented at ASCO Annual Meeting 2011; 3-7 June 2011; Chicago, Illinois. J Clin Oncol 2011;29(Suppl. 15):A7503.
39. Lee JS, Park K, Kim SW, Lee DH, Kim HT, Han JT, et al. A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009;4:S283.
40. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. http://dx.doi.org/10.1016/S1470-2045(11)70393-X
41. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent IRESSA versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8. http://dx.doi.org/10.1200/JCO.2011.36.8456
42. Leary AF, de Castro DG, Nicholson AG, Ashley S, Wotherspoon A, O'Brien MER, et al. Establishing an EGFR mutation screening service for non-small cell lung cancer: sample quality criteria and candidate histological predictors. Eur J Cancer 2012;48:61-7. http://dx.doi.org/10.1016/j.ejca.2011.09.022
43. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-55. http://dx.doi.org/10.1158/1078-0432.CCR-06-0260
44. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-6. http://dx.doi.org/10.1200/JCO.2006.07.5754
45. Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, et al. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Clin Lung Cancer 2012;13:129-35. http://dx.doi.org/10.1016/j.cllc.2011.08.004
46. Yang C-H, Yu C-J, Shih J-Y, Chang Y-C, Hu F-C, Tsai M-C, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-53. http://dx.doi.org/10.1200/JCO.2007.15.6695
47. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8. http://dx.doi.org/10.1056/NEJMoa0909530
48. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74. http://dx.doi.org/10.1200/JCO.2010.33.4235
49. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. http://dx.doi.org/10.1056/NEJMoa0810699
50. Ohe Y, Ishikura S, Yokoyama A, Atagi S, Shibata T, Tamura T, et al. Safety and efficacy trial of cisplatin (P) and vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). 4th Asia Pacific Lung Cancer Conference, APLCC, Seoul, 2-4 December 2010. J Thorac Oncol 2010;5(Suppl. 5):401-2.
51. AstraZeneca UK Ltd. Single Technology Appraisal (STA) for Gefitinib for the first line treatment of locally advanced or metastatic non-small lung cancer (submission to National Institute for Health and Clinical Excellence) [Word document provided by AstraZeneca]. Luton, UK: AstraZeneca UK Ltd, 2010 (accessed 18 July 2012).
52. Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, et al. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. Eur Respir J 2012;39:172-9. http://dx.doi.org/10.1183/09031936.00201210
53. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83. http://dx.doi.org/10.1136/bmj.313.7052.275
54. Arrieta O, Anaya P, Lopez RJ, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with advanced non small-cell lung cancer (ANSCLC) treated with gefitinib or carboplatin-paclitaxel. Paper presented at 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2010); 15-19 May 2010; Atlanta, GA. Value Health 2010;13(Suppl. 3):A37-8. http://dx.doi.org/10.1016/S1098-3015(10)72164-1
55. Chen W, Ellis P, Levin L, Krahn M. Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario. Paper presented at 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 21-25 May 2011; Baltimore, MD. Value Health 2011;14:A82. http://dx.doi.org/10.1016/j.jval.2011.02.459
56. Jacob J, Henriksson M, Brattström D. Cost-effectiveness of gefitinib versus doublet chemotherapy in first-line treatment of non-small cell lung cancer (NSCLC) in Sweden. Paper presented at ISPOR 13th Annual European Congress; 6-9 November 2010; Prague. Value Health 2010;13:A270. http://dx.doi.org/10.1016/S1098-3015(11)71995-7
57. Lopes GD, Segel J, Tan D, Do Y, Mok T, Finkelstein E. Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer. EJC Suppl 2011;9:2.
58. Shiroiwa T, Miyoshi Y, Tsutani K. Cost-effectiveness analysis of EGFR testing and gefitinib for nonsmall-cell lung cancer (NSCLC) in Japan. Paper presented at 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2-6 June 2012; Washington, DC. Value Health 2012;15:A67.
59. Cadranel J, Coudert B, Mauguen A, Friard S, Quoix E, Madelaine J, et al. Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort. Eur Respir J 2010;1(Suppl. 54):1942.
60. Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, et al. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol 2011;6:161-8. http://dx.doi.org/10.1097/JTO.0b013e318200f4c1
61. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes 2008;6:84. http://dx.doi.org/10.1186/1477-7525-6-84
62. Curtis L. Unit Costs of Health and Social Care. Canterbury: PSSRU, University of Kent, 2011. www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf (accessed 18 December 2012).
63. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67. http://dx.doi.org/10.1056/NEJMoa0904554
64. Cantor AB. Projecting the standard error of the Kaplan-Meier estimator. Stat Med 2001;20:2091-7. http://dx.doi.org/10.1002/sim.856
65. Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010;14(Suppl. 2):71-9.
66. National Institute for Health and Clinical Excellence (NICE). Erlotinib for the Treatment of Non-Small-Cell Lung Cancer (TA162). London: NICE; 2008. http://publications.nice.org.uk/erlotinib-for-the-treatment-of-non-small-cell-lung-cancer-ta162 (accessed 22 May 2013).
67. Eli Lilly and Company Ltd. Single Technology Appraisal (STA) for Pemetrexed for the First Line Treatment of Non-Small Cell Lung Cancer (submission to National Institute for Health and Clinical Excellence): Eli Lilly and Company Ltd; 2008. www.nice.org.uk/nicemedia/live/12045/43762/43762.pdf (accessed 18 December 2012).
68. Roche Products Ltd. Tarceva (erlotinib): NICE STA Submission. Achieving Clinical Excellence in the Treatment of Relapsed Non-Small Cell Lung Cancer. Roche Submission to the National Institute for Health and Clinical Excellence: Roche Products Ltd; 2006. www.nice.org.uk/nicemedia/pdf/Lungcancer_erlotinib_manusub.pdf (accessed 4 December 2012).
69. Department of Health (DoH). NHS Reference Costs 2011-2012. London: DoH; 2012. www.dh.gov.uk/health/2012/11/2011-12-reference-costs/(accessed 4 December 2012).
70. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. http://dx.doi.org/10.1016/S1470-2045(09)70364-X
71. Wang F, Wang LD, Li B, Sheng ZX. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials. Clin Oncol 2012;24:396-401. http://dx.doi.org/10.1016/j.clon.2011.09.013
72. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012;131:E822-9. http://dx.doi.org/10.1002/ijc.27396
73. Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 2011;22:2277-85. http://dx.doi.org/10.1093/annonc/mdq742
74. Whiting P, Westwood M, Beynon R, Burke M, Sterne JA, Glanville J. Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies. J Clin Epidemiol 2011;64:602-7. http://dx.doi.org/10.1016/j.jclinepi.2010.07.006
75. National Institute for Health and Clinical Excellence (NICE). Erlotinib Monotherapy for Maintenance Treatment of Non-Small-Cell Lung Cancer. NICE technology appraisal guidance 227. London: NICE, 2011. http://guidance.nice.org.uk/TA227 (accessed 10 July 2012).
76. Schwander B, De Castro Carpeno J, Heigener DF, Wright E, Bischoff HG, Walzer S. Comparative effectiveness assessment of erlotinib versus gefitinib in first-line EGFR activating mutation positive non-small cell lung cancer. Paper presented at 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 21-25 May 2011; Baltimore, MD. Value Health 2011;14:A155. http://dx.doi.org/10.1016/j.jval.2011.02.865
77. Wu WS, Chen YM, Tsai CM, Shih JF, Chiu CH, Chou KT, et al. Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Exp Ther Med 2012;3:207-13.
78. Zhou Q, Zhang X-C, Chen Z-H, Yin X-L, Yang J-J, Xu C-R, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3316-21. http://dx.doi.org/10.1200/JCO.2010.33.3757
79. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008;3:832-9. http://dx.doi.org/10.1097/JTO.0b013e31818071f3
80. Beau-Faller M, Prim N, Ruppert A-M, Nanni I, Besse B, Escande F, et al. Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: clinical, molecular, and survival data. Paper presented at ASCO Annual Meeting 2012; 1-5 June 2012; Chicago, IL. J Clin Oncol 2012;30(Suppl. 15):Abstract 10507.
81. Schuette W, Eberhardt WEE, von der Schulenburg J-MG, Dietel M, Schirmacher P, Zaun S, et al. EGFR mutation analysis from REASON: a registry for the epidemiologic and scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. Paper presented at ASCO Annual Meeting 2012; 1-5 June 2012; Chicago, IL. J Clin Oncol 2012;30(Suppl. 15):Ae18016.
82. Normanno N, Pinto C, Taddei GL, Mari E, Troncone G, Graziano P, et al. EGFR FASTnet: the Italian network for epidermal growth factor receptors (EGFR) mutation analysis in non-small cell lung cancer (NSCLC). Paper presented at ASCO Annual Meeting; 3-7 June 2011; Chicago, IL. J Clin Oncol 2011;29(Suppl. 1):e18026.
83. Normanno N, Pinto C, Taddei GL, Troncone G, Graziano P, De Maglio G, et al. Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. Paper presented at ASCO Annual Meeting 2012; 1-5 June 2012; Chicago, IL. J Clin Oncol 2012;30(Suppl. 15):e18021.
84. Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, et al. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer Chemother Pharmacol 2012;70:315-20. http://dx.doi.org/10.1007/s00280-012-1876-0
85. Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 2011;102:1032-7. http://dx.doi.org/10.1111/j.1349-7006.2011.01887.x
86. Qiagen. Therascreen® RGQ PCR kits: for mutation detection in the EGFR and KRAS oncogenes. Limburg, the Netherlands: Qiagen; 2012.
87. Qiagen. Therascreen® Cancer Panel Pyro® Kits: for KRAS, BRAF, NRAS, and EGFR gene mutation detection. Limburg, the Netherlands: Qiagen; 2011.
88. Chen Y-M, Tsai C-M, Fan W-C, Shih J-F, Liu S-H, Wu C-H, et al. Phase II randomized trial of erlotinib or vinorelbine in chemo-naive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012;7:412-18.
89. Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012;17:863-70. http://dx.doi.org/10.1634/theoncologist.2011-0426
90. Yang CH, Fukuoka M, Mok TS, Wu YL, Thongprasert S, Saijo N, et al. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). Paper presented at 35th ESMO Congress; 8-12 October 2010; Milan. Ann Oncol 2010;21:1-2.
91. Ohe Y, Ichinose Y, Nishiwaki Y, Yamamoto N, Negoro S, Duffield E, et al. Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): evaluation of recruits in Japan. Paper presented at 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO); 29 May to 2 June 2009; Orlando, FL. J Clin Oncol 2009;27(Suppl. 1):8044.
92. Wu Y, Mok T, Chu D, Han B, Liu X, Zhang L, et al. Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Paper presented at Annual Meeting of the American Society of Clinical Oncology (ASCO); 29 May to 2 June 2009; Orlando, FL. J Clin Oncol 2009;27(Suppl. 1):8041.
93. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). Paper presented at 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO); 29 May to 2 June 2009; Orlando, FL. J Clin Oncol 2009;27(Suppl. 1):8006.
94. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (PTS) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Paper presented at 34th Congress of the European Society for Medical Oncology (ESMO); 12-16 September 2008; Stockholm. Ann Oncol 2008;19:1.
95. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54-9. http://dx.doi.org/10.1093/annonc/mds214
96. Minegishi Y, Inoue A, Kobayashi K, Gemma A, Maemondo M, Oizumi S, et al. First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. EJC Suppl 2009;7:25. http://dx.doi.org/10.1016/S1359-6349(09)72190-1
97. Kinoshita I, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, et al. Phase III study of gefitinib versus chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) as first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations: North East Japan Gefitinib Study group trial 002 (NEJ002). Paper presented at 14th Congress of the APSR and 3rd Joint Congress of the APSR/ACCP; 14-18 November 2009; Seoul. Respirology 2009;14:A127.
98. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009;27:2.
99. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Saijo Y, et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinary Congress; 20-24 September 2009; Berlin. Eur J Cancer Suppl 2009;7:6. http://dx.doi.org/10.1016/S1359-6349(09)72038-5
100. De Marinis F, Rosell R, Vergnenegre A, Massuti B, Felip E, Gervais R, et al. Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) activating mutations: the EURTAC phase II randomized trial interim results. Paper presented at 2011 European Multidisciplinary Cancer Congress; 23-27 September 2011; Stockholm. Eur J Cancer 2011;47:S597. http://dx.doi.org/10.1016/S0959-8049(11)72328-0
101. Zhou C, Wu YL, Chen G, Feng JF, Liu X, Wang C, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). Paper presented at ASCO Annual Meeting; 3-7 June 2011; Chicago, IL. J Clin Oncol 2011;29(Suppl. 1): 1-4
102. Wang CL, Zhou C, Wu YL, Lu S, Zhang L, Zhang Y, et al. First-line erlotinib vs gemcitabine/carboplatin (GC) in activating EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): efficacy and safety results from phase III optimal study in Chinese patients (pts). Paper presented at 4th Asia Pacific Lung Cancer Conference (APLCC); 2-4 December 2010; Seoul. J Thorac Oncol 2010;5(Suppl. 5):S373-4.
103. Liu X, Wu Y, Zhou C, Lu S, Zhang L, Zhi X, et al. Biomarker analyses from the phase III, randomized, openlabel, OPTIMAL study of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations. Paper presented at Chicago Multidisciplinary Symposium in Thoracic Oncology; 9-11 December 2010; Chicago, IL. J Thorac Oncol 2010;5(Suppl. 7):514-15.
104. Wang J, Zhou C, Wu Y, Lu S, Zhang L, Zhang Y, et al. Optimal: phase III study of first-line erlotinib versus gemcitabine plus carboplatin (GC) in Chinese patients (pts) with activating EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Paper presented at Chicago Multidisciplinary Symposium in Thoracic Oncology; 9-11 December 2010; Chicago, IL. J Thorac Oncol 2010;5(Suppl. 7):507-8.
105. Wu YL, Zhou C, Chen G, Feng J, Liu X, Wang C, et al. First biomarker analyses from a phase III, randomised, open-label, first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (PTS) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (optimal, CTONG-0802). Paper presented at 35th ESMO Congress; 8-12 October 2010; Milan. Ann Oncol 2010;21:6.
106. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang C, et al. Efficacy results from the randomised phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Paper presented at 35th ESMO Congress; 8-12 October 2010; Milan. Ann Oncol 2010;21:6.
107. Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C, et al. Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). Paper presented at Annual Meeting of the American Society of Clinical Oncology (ASCO); 4-8 June 2010; Chicago, IL. J Clin Oncol 2010; 28(Suppl. 1):7575.
108. Teck LW, Huat TB, Ravindran K, Balram C. EGFR mutational status and clinical outcome to gefitinib monotherapy in chemo-naive non-small-cell lung cancer patients. Pharmacogenomics 2008;9:1382.
109. AstraZeneca Ltd. First-Line Treatment for Adenocarcinoma Patients with Epidermal Growth Factor Receptor (EGFR) Mutation. NCT00344773. Bethesda, MD: National Library of Medicine; 2010. http://ClinicalTrials.gov/show/NCT00344773 (accessed 18 July 2012).
110. Chinese PLA General Hospital. A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma with EGFR Mutations. NCT01131429. Bethesda, MD: National Library of Medicine; 2010. http://ClinicalTrials.gov/show/NCT01131429 (accessed 4 December 2012).
111. Ahn M-J, Park B-B, Ahn JS, Kim SW, Kim H-T, Lee JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008;14:3860-6. http://dx.doi.org/10.1158/1078-0432.CCR-07-4608
112. Aydiner A. Efficacy of gefitinib in patients with epidermal growth factor receptor mutation positive advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Paper presented at 2011 European Multidisciplinary Cancer Congress; 23-27 September 2011; Stockholm. Eur J Cancer 2011;47:S630.
113. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55. http://dx.doi.org/10.1093/jnci/dji112
114. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2009;135:1483-93. http://dx.doi.org/10.1007/s00432-009-0595-3
115. Chang C-H, Chen K-Y, Young-Xu Y, Kurth T, Orav EJ, Yang P-C, et al. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. Lung Cancer 2008;62:242-52. http://dx.doi.org/10.1016/j.lungcan.2008.03.001
116. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 2011;67:235-43. http://dx.doi.org/10.1007/s00228-010-0965-4
117. Chou T-Y, Chiu C-H, Li L-H, Hsiao C-Y, Tzen C-Y, Chang K-T, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:3750-7. http://dx.doi.org/10.1158/1078-0432.CCR-04-1981
118. Chung KP, Wu SG, Wu JY, Yang JH, Yu CJ, Wei PF, et al. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res 2012;18:3470-7. http://dx.doi.org/10.1158/1078-0432.CCR-11-2353
119. Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2010;116:4309-17. http://dx.doi.org/10.1002/cncr.25214
120. Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer 2006;107:2858-65. http://dx.doi.org/10.1002/cncr.22331
121. Cohen VA, Jarry JS, Batist J, Small G, Kreisman D, Tejada H, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in non-small-cell lung cancer. Cancer 2006;107:2858-65.
122. Crosby C, Smye-Rumsby T, Plummeridge M, Braybrooke J, Dangoor A, De Winton E, et al. EGFR mutation testing in non-small cell lung cancer: the Bristol experience. J Med Genet 2011;48:S101.
123. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303. http://dx.doi.org/10.1158/1078-0432.CCR-09-1660
124. de Braud F, Noberasco C, Curigliano G, De Pas M, Dodaro L, Manzoni S, et al. Correlation between epidermal growth factor receptor expression and tumour response in patients with advanced non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839). Br J Cancer 2003;89:S27.
125. De Greve J, Van Meerbeeck JP, Vansteenkiste JF, Teugels E, Geers C, Meert A, et al. First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: a multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)-FIELT study group. Paper presented at ASCO Annual Meeting 2011; 3-7 June 2011; Chicago, IL. J Clin Oncol 2011;29(Suppl. 1):7597.
126. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6:1895-901. http://dx.doi.org/10.1097/JTO.0b013e318227e8c6
127. Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: NICE single technology appraisal. Pharmacoeconomics 2011;29:1051-62. http://dx.doi.org/10.2165/11591600-000000000-00000
128. Eaton H, Dutton L, Wallace AJ, Howard E, Gaunt L, Blackhall F, etal. Epidermal Growth Factor Receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients. J Med Genet 2011;48:S72.
129. Eberhardt W, Thomas M, von der Schulenburg JMG, Dietel M, Schirmacher P, Gutendorf B, etal. EGFR mutation testing and first line treatment of patients with advanced NSCLC and positive EGFR mutation status: results from a German registry. Eur J Cancer 2011;47:S636. http://dx.doi.org/10.1016/S0959-8049(11)72456-X
130. Edwards SJ, Welton N, Borrill J. Tolerability of first-line treatments of locally advanced or metastatic non-small-cell lung cancer (NSCLC): a systematic review and adjusted indirect comparison. Paper presented at ISPOR 13th Annual European Congress; 6-9 November 2011; Prague. Value Health 2010;13:A250. http://dx.doi.org/10.1016/S1098-3015(11)71898-8
131. Edwards SJ, Welton N, Borrill J. Gefitinib compared with doublet chemotherapy for first-line treatment of non-small-cell lung cancer (NSCLC): a systematic review and adjusted indirect comparison. Paper presented at ISPOR 13th Annual European Congress; 6-9 November 2010; Prague. Value Health 2010;13:A252-3. http://dx.doi.org/10.1016/S1098-3015(11)71908-8
132. Enting D, Januszewski A, Benepal T. EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review. Lung Cancer 2012;75:S5. http://dx.doi.org/10.1016/S0169-5002(12)70014-4
133. Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol 2006;1:367-76. http://dx.doi.org/10.1097/01243894-200605000-00018
134. Feng JF, Wu YL, Zhou CC, Lu S, Zhang L, Zhi XY, et al. Additional biomarker analyses from the phase III OPTIMAL study of first-line erlotinib versus gemcitabine/carboplatin (GC) in Chinese patients (pts) with advanced activating EGFR mutation-positive non-small cell lung cancer (NSCLC). J Thorac Oncol 2010;5:S395.
135. Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials. Anticancer Drugs 2011;22:842-52. http://dx.doi.org/10.1097/CAD.0b013e328349c303
136. Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60. http://dx.doi.org/10.1200/JCO.2008.18.4408
137. Gracia M, Majem M, Aguillo MTM, Banaclocha NM, Provencio M, Arriola E, et al. Effect of sample type and turnaround time (TAT) on the feasibility of non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutation testing in routine clinical practice: results from the Spanish REASON study. EurJ Cancer 2011;47:S255. http://dx.doi.org/10.1016/S0959-8049(11)71185-6
138. Gupta R, Dastane AM, McKenna R, Marchevsky AM. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current 'best evidence' with meta-analysis. Hum Pathol 2009;40:356-65.
139. Han SW, Jeong S, Choi IS, Kim DN, Chung DH, Im SA, et al. EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC). J Clin Oncol 2005;23:S639.
140. Han S-W, Kim T-Y, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501. http://dx.doi.org/10.1200/JCO.2005.01.388
141. Han S-W, Kim T-Y, Lee K-H, Hwang PG, Jeon YK, Oh D-Y, et al. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer 2006;54:201-7. http://dx.doi.org/10.1016/j.lungcan.2006.07.007
142. Han Y, Xu J, Duan HQ, Song ST, Liu XQ, Zhang Y, et al. EGFR mutation predicts response and prognosis in IRESSA-treated advanced-stage non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2007;29:278-83.
143. Hata A, Katakami N, Kunimasa K, Yoshioka H, Fujita S, Kaji R, et al. How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene-sensitive mutations? Paper presented at ASCO Annual Meeting 2011; 3-7 June 2011; Chicago, IL. J Clin Oncol 2011;29(Suppl. 1):A7609.
144. Hou M-M, Huang S-F, Kuo H-P, Yang C-T, Tsai Y-H, Yu C-T, et al. Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations. Anticancer Res 2012;32:1107-12.
145. Hsieh M-H, Fang Y-F, Chang W-C, Kuo H-P, Lin S-Y, Liu H-P, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006;53:311-22. http://dx.doi.org/10.1016/j.lungcan.2006.06.005
146. Ibrahim EM. Frontline gefitinib in advanced non-small cell lung cancer: meta-analysis of published randomized trials. Ann Thorac Med 2010;5:153-60. http://dx.doi.org/10.4103/1817-1737.65047
147. Inoue A, Kobayashi K, Usui K, Maemondo M, Ando M, Gemma A, et al. Gefitinib provides an beneficial treatment to poor PS or super-elderly patients with EGFR mutation-positive NSCLC (North-East Japan Gefitinib Study Group). Ann Oncol 2008;19:106.
148. Inoue A, Minegishi Y, Maemondo M, Okinaga S, Morikawa N, Kobayashi K, et al. A final results of a phase II study of first-line gefitinib for elderly patients (PTS) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study. Paper presented at 35th ESMO Congress; 8-12 October 2010; Milan. Ann Oncol 2010;21:141-142.
149. Jackman DM, Miller VA, Cioffredi L-A, Yeap BY, Janne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-73. http://dx.doi.org/10.1158/1078-0432.CCR-09-0888
150. Johnson BE, Lucca J, Rabin MS, Lynch TJ, Ostler P, Skarin AT, et al. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol 2004;22:S636.
151. Kasahara K, Sone T, Kimura H, Nishio K, Tamura T, Shibata K, et al. Correlation between epidermal growth factor receptor gene status and clinical outcome of gefitinib in Japanese patients with non-small cell lung cancer. J Clin Oncol 2006;24:S412.
152. Kashii T, Okamoto I, Urata Y, Hirashima T, Kudoh S, Ichinose Y, et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (PTS): results of West Japan Thoracic Oncology Group Trial (WJTOG0403). Ann Oncol 2006;17:215.
153. Kim YH, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, et al. EGFR mutation: significance as a stratification factor in the era of molecular-targeted therapy. Oncol Lett 2011;2:383-7. http://dx.doi.org/10.3892/ol.2011.240
154. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21. http://dx.doi.org/10.1158/1078-0432.CCR-05-2324
155. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97:778-84. http://dx.doi.org/10.1038/sj.bjc.6603949
156. Kris M, Mok T, Kim E, Douillard JY, Fukuoka M, Thatcher N. Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinary Congress; 20-24 September 2009; Berlin. Eur J Cancer Suppl 2009;7:505-6. http://dx.doi.org/10.1016/S1359-6349(09)71716-1
157. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011;74:469-73. http://dx.doi.org/10.1016/j.lungcan.2011.04.008
158. Kunimasa K, Katakami N, Masago K, Yoshioka H, Tomii K, Kaneda T, et al. Customized chemotherapy on the basis of EGFR mutation status for elderly patients with advanced non-small-cell lung cancer. Paper presented at European Multidisciplinary Cancer Congress; 23-27 September 2011; Stockholm: Sweden. Eur J Cancer 2011;47:S280. http://dx.doi.org/10.1016/S0959-8049(11)71267-9
159. Lee DH, Kim S-W, Suh C, Han YH, Lee J-S. Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemother Pharmacol 2011;67:35-9. http://dx.doi.org/10.1007/s00280-010-1280-6
160. Lee DH, Song HJ, Lee YM, Choi YH, Kim SW, Suh C, et al. Prospective study of erlotinib comparing chemotherapy-naive non-small cell lung cancer patients having an activating mutation in EGFR gene with those having wild-type EGFR gene. EJC Suppl 2008;6:68. http://dx.doi.org/10.1016/S1359-6349(08)72147-5
161. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9. http://dx.doi.org/10.1200/JCO.2007.13.2720
162. Liu S, Wang D, Chen B, Wang Y, Zhao W, Wu J. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2011;73:203-10. http://dx.doi.org/10.1016/j.lungcan.2010.12.006
163. Massuti B, Moran T, Porta R, Queralt C, Cardenal F, Mayo C, et al. Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: final results of the Spanish Lung Cancer Group (SLCG) trial. Paper presented at Annual Meeting of the American Society of Clinical Oncology (ASCO); 2 May - 2 June 2009; Orlando, FL. J Clin Oncol 2009;27(Suppl. 1):8023.
164. Massuti B, Porta R, Paz-Ares L, Cardenal F, Lopez-Vivanco G, Provencio M, et al. First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Lung Cancer 2006;52:S25-6.
165. Massuti B, Reguart N, Vivanco GL, Provencio M, Isla D, Camps C, et al. First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Ann Oncol 2006;17:216.
166. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-81. http://dx.doi.org/10.1183/09031936.02.00296502
167. Miller VA, Zakowski M, Riely GJ, Pao W, Hussain S, Ladanyi M, et al. EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC. J Clin Oncol 2005;23:S628.
168. Minegishi Y, Maemondo M, Okinaga S, Morikawa N, Inoue A, Kobayashi K, et al. First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: multicenter phase II trial (NEJ 003 study). Paper presented at Annual Meeting of the American Society of Clinical Oncology (ASCO); 4-8 June 2010; Chicago, IL. J Clin Oncol 2010;28(Suppl. 1):A7561.
169. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15:4493-8. http://dx.doi.org/10.1158/1078-0432.CCR-09-0391
170. Murray S, Evangelou E, Linardou H, Dahabreh IJ, Kosmidis P, Bafaloukos D, et al. Predictive significance of EGFR somatic mutations and gene copy number in NSCLC patients treated with single agent tyrosine kinase inhibitors: a systematic review and meta-analysis. Paper presented at 2nd European Lung Cancer Conference; 28 April to 1 May 2010; Geneva. J Thorac Oncol 2010;5(Suppl. 1):55-6.
171. Murray S, Evangelou E, Linardou H, Kosmidis P, Bafaloukos D, Ioannidis J. Predictive and prognostic significance of somatic mutations in the tyrosine kinase (TK) domain of EGFR in NSCLC patients treated with single agent gefitinib: a systematic review and meta-analysis. Paper presented at 34th Congress of the European Society for Medical Oncology (ESMO); 23-16 September 2008, Stockholm. Ann Oncol 2008;19:105.
172. Na II, Rho JK, Choi YJ, Kim CH, Koh JS, Ryoo B-Y, et al. Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J Korean Med Sci 2007;22:393-9. http://dx.doi.org/10.3346/jkms.2007.22.3.393
173. Naoki K, Okamoto H, Soejima K, Nakachi I, Fujii T, Hida N, et al. New sensitive methods to detect EGFR gene mutations in lung cancer specimens, structure-specific flap endonuclease based method; comparison with direct sequencing. Paper presented at 34th Congress of the European Society for Medical Oncology (ESMO); 23-16 September 2008; Stockholm. Ann Oncol 2008;19:106.
174. Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, Nakachi I, et al. The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. IntJ Clin Oncol 2011;16:335-44.
175. Okamoto I, Kashii T, Urata Y, Hirashima T, Kudoh S, Ichinose Y, et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): results of West Japan Thoracic Oncology Group trial (WJTOG0403). J Clin Oncol 2006;24:S382.
176. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007;97:1560-6. http://dx.doi.org/10.1038/sj.bjc.6604068
177. Park SH, Ha SY, Lee J-I, Lee H, Sim H, Kim YS, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 2009;24:448-52. http://dx.doi.org/10.3346/jkms.2009.24.3.448
178. Paz-Ares L, Soulieres D, Klughammer B, Melezinek I, Moecks J, Keil L, et al. Clinical outcomes in patients with EGFR mutations: pooled analysis of NSCLC patients treated with either an EGFR TKI or chemotherapy. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinar Congress; 20-24 September 2009; Berlin. EurJ Cancer Suppl 2009;7:551-2.
179. Paz-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010; 14:51-69. http://dx.doi.org/10.1111/j.1582-4934.2009.00991.x
180. Paz-Ares L, Sanchez JM, Garcia-Velasco A, Massuti B, Lopez-Vivanco G, Provencio M, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006;24:S369.
181. Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009;29:2767-73.
182. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13:107-14. http://dx.doi.org/10.1016/j.cllc.2011.08.005
183. Petruzelka L. Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut plus). Lung Cancer 2012;77:S25. http://dx.doi.org/10.1016/j.lungcan.2012.05.042
184. Plant R, Chetiyawardana S, Thompson J, Williams S, Ghafoor Q. Use of Gefitinib (Iressa) in patients with EGFR positive NSCLC in the Pan Birmingham Cancer Network. Paper presented at 10th Annual British Thoracic Oncology Group Conference (BTOG); 25-27 January 2012; Dublin. Lung Cancer 2012;75:S6. http://dx.doi.org/10.1016/S0169-5002(12)70018-1
185. Reck M, Heller A, Foernzler D, Moecks J, Ward C, De Rosa F, et al. Molecular markers such as EGFR and kRAS mutations as predictors of sensitivity to erlotinib in patients (pts) with NSCLC: exploratory subanalyses of TALENT, a phase III trial. Lung Cancer 2005;49:S112.
186. Ricciardi S, Tedesco B, Migliorino MR, Graziano P, Leone A, Di Salvia M, et al. EGFR mutations in patients with non-small cell lung cancer (NSCLC) and correlation with sensitivity to erlotinib. EJC Suppl 2008;6:134. http://dx.doi.org/10.1016/j.ejcsup.2008.06.065
187. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44. http://dx.doi.org/10.1158/1078-0432.CCR-05-1846
188. Rizvi N, Pao W, Miller V, Rusch V, Heelan R, Ladanyi M, et al. A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC. Lung Cancer 2005;49:S43. http://dx.doi.org/10.1016/S0169-5002(05)80257-0
189. Satouchi M, Mitsudomi T, Ebi N, Saka H, Sawa Y, Sasaki J, et al. A phase III trial of gefitinib versus cisplatin/docetaxel for NSCLC patients with activating EGFR mutation; WJTOG 3405. Ann Oncol 2010;21:11.
190. Schneider C-P, Heigener D, Schott-von-Romer K, Gutz S, Laack E, Digel W, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008;3:1446-53. http://dx.doi.org/10.1097/JTO.0b013e31818ddcaa
191. Shih J-Y, Gow C-H, Yu C-J, Yang C-H, Chang Y-L, Tsai M-F, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-9. http://dx.doi.org/10.1002/ijc.21458
192. Shukuya T, Takahashi T, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, et al. The efficacy of gefitinib for non-adeno non-small-cell lung cancer patients harboring EGFR mutations: a pooled analysis. J Thorac Oncol 2010;5:S393.
193. Sone T, Kasahara K, Kimura H, Nishio K, Mizuguchi M, Nakatsumi Y, et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with non-small cell lung cancer. Cancer 2007;109:1836-44.
194. Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, et al. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol 2011;137:687-94. http://dx.doi.org/10.1007/s00432-010-0928-2
195. Sunaga N, Yanagitani N, Kaira K, Tomizawa Y, Iijima H, Otani Y, et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. J Clin Oncol 2006;24:S409.
196. Sutani A, Nagai Y, Udagawa K, Uchida Y, Murayama Y, Tanaka T, et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. J Clin Oncol 2006;24:S383.
197. Takano T, Ohe Y, Furuta K, Tsuta K, Nomoto K, Matsuno Y, et al. EGFR mutations detected by high-resolution melting analysis (HRMA) as a predictor of response and survival in non-small cell lung cancer (NSCLC) patients treated with gefitinib. J Clin Oncol 2006;24:S382.
198. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37. http://dx.doi.org/10.1200/JCO.2005.01.0793
199. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385-90. http://dx.doi.org/10.1158/1078-0432.CCR-07-0627
200. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
201. Tsai CM, Chiu CH, Chou TY, Li LH, Hsiao CY, Chen M, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. J Clin Oncol 2005;23:S641.
202. Tsurutani J, Mitsudomi T, Mori S, Okamoto I, Kaname N, Tada H, et al. A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growth factor receptor (EGFR) gene: a preliminary results of WJTOG 3405. Paper presented at Joint ECCO 15-34th ESMO Multidisciplinar Congress; 20-24 September 2009; Berlin. EurJ Cancer Suppl 2009;7:505. http://dx.doi.org/10.1016/S1359-6349(09)71715-X
203. Tyagi P. Updated data from the Iressa survival in lung cancer trial. Clin Lung Cancer 2005;6:340-2. http://dx.doi.org/10.1016/S1525-7304(11)70364-3
204. van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro-and prospective observations in non-small-cell lung cancer. Ann Oncol 2007;18:99-103. http://dx.doi.org/10.1093/annonc/mdl323
205. Villaflor VM, Buckingham L, Gale M, Coon J, Mauer AM, MuzzafarT, et al. EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2005;23:S639.
206. Wang T, Ma L. [Pooled analysis of the trials of erlotinib monotherapy for epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer.] Zhongguo Fei Ai Za Zhi 2009;12:1237-41.
207. Webb S, Thomas M, Metcalf C, Segal A, Nowak AK, Bentel J, et al. EGFR mutation testing in NSCLC: patterns of care and outcomes in Western Australia. Asia Pac J Clin Oncol2009;5:66-71. http://dx.doi.org/10.1111/j.1743-7563.2009.01192.x
208. Won Y-W, Han J-Y, Lee GK, Park S-Y, Lim KY, Yoon K-A, et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol 2011;64:947-52. http://dx.doi.org/10.1136/jclinpath-2011-200169
209. Wu J-Y, Shih J-Y, Chen K-Y, Yang C-H, Yu C-J, Yang P-C. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine 2011;90:159-67. http://dx.doi.org/10.1097/MD.0b013e31821a16f4
210. Wu J-Y, Wu S-G, Yang C-H, Chang Y-L, Chang Y-C, Hsu Y-C, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2011;72:205-212. http://dx.doi.org/10.1016/j.lungcan.2010.08.013
211. Wu J-Y, Yu C-J, Chang Y-C, Yang C-H, Shih J-Y, Yang P-C. Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-21. http://dx.doi.org/10.1158/1078-0432.CCR-10-3408
212. Wu J-Y, Yu C-J, Yang C-H, Wu S-G, Chiu Y-H, Gow C-H, et al. First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008;178:847-53. http://dx.doi.org/10.1164/rccm.200803-389OC
213. Wu Y-L, Zhong W-Z, Li L-Y, Zhang X-T, Zhang L, Zhou C-C, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007;2:430-9. http://dx.doi.org/10.1097/01.JTO.0000268677.87496.4c
214. Wu Y, Zhong W, Li L, Zhang L, Zhou C, Liu W, et al. EGFR mutations and the correlation with gefitinib therapy in Chinese NSCLC: a systematic review based on individual patient data from 5 medical centers in China. J Clin Oncol 2006;24:S410.
215. Xu C, Zhou Q, Wu YL. Meta-analysis of the chemotherapy versus EGFR-TKI in different selections of patients. Paper presented at ASCO Annual Meeting; 3-7 June 2011; Chicago, IL. J Clin Oncol 2011;29(Suppl. 1):A7600.
216. Yang J, Wu YL, Saijo N, Thongprasert S, Chu DT, Chen YM, et al. Efficacy outcomes in first-line treatment of advanced NSCLC with gefitinib (G) vs carboplatin/paclitaxel (C/P) by epidermal growth factor receptor (EGFR) gene-copy number score and by most common EGFR mutation subtypes. Exploratory data from IPASS. Paper presented at 2011 European Multidisciplinary Cancer Congress; 23-27 September 2011; Stockholm. Eur J Cancer 2011;47:A633. http://dx.doi.org/10.1016/S0959-8049(11)72444-3
217. Yoshida K, Okamoto I, Kobayashi K, Sunaga N, Sugio K, Inoue A, et al. Comparison of the efficacy between chemotherapy and gefitinib as 1st line setting in patients with EGFR mutation positive NSCLC. Paper presented at 34th Congress of the European Society for Medical Oncology (ESMO); 12-16 September 2008; Stockholm: Sweden. Ann Oncol 2008;19:104.
218. Yoshida K, Yatabe Y, Park J, Ogawa S, Park JY, Shimizu J, et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol 2010;136:527-35. http://dx.doi.org/10.1007/s00432-009-0685-2
219. Zhang XH, Li C, Dai CF, Zhou BS. Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: a meta-analysis. Thoracic Cancer 2011;2:101-8. http://dx.doi.org/10.1111/j.1759-7714.2011.00051.x
220. Zhang X, Xu L, Wang H, Zhu Y, Liu Z, Yue W, et al. The relationship between EGFR mutations and response and prognosis of tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi 2008;11:206-13.
221. Zhong W, Xia Y, Wang MZ, Chen MJ, Zhang L, Zhao J, et al. EGFR gene mutations in advanced non-small cell lung cancer and its influence on effect of gefitinib. Respirology 2011;16:146.